Brent R. Constantz Ph.D.
Brent R. Constantz, Ph.D. is founder, president, chief executive officer and chief scientist of Norian Corporation in Cupertino, California. Norian Corporation produces Norian SRS=AE (Skeletal Repair System=AE), a cancellous bone cement sets rapidly, allowing immediate fracture stabilization and an early return to function. Brent R. Constantz, Ph.D. is interested in biomineralization and the design of mineralized structures and their function. He has investigated skeletogenetic processes in every animal phylum. Most of his work has been on reef building corals and mammalian bone. In the orthopaedic medical device area, he formed Norian Corporation in 1987, the original player in synthetic bone cement for bone fixation and replacement. He served as President & Chief Executive Officer at Norian, now a subsidiary of Synthes Inc., until coming to Stanford as a Visiting Scholar in 1998. A Consulting Associate Professor teaching Biomineralization (ME/GES 282) and Mineralization of Bone (ME/GES 285) in the Biomechanical Engineering Division, & Geological & Environmental Sciences, Dr. Constantz formed his second medical device company, Corazon Technologies, Inc., in 1999 where he served as President & Chief Executive Officer until 2002. Corazón is a cardiovascular device company based in Menlo Park addressing pathological calcification of the cardiovascular system. Currently, he serves as President & Chief Executive Officer of Skeletal Kinetics LLC, in Cupertino, California. Skeletal Kinetics produces a second generation fracture repair cement that allow patients to return to functional soon after skeletal fractures. Dr. Constantz received a doctorate in Earth Sciences at the University of California at Santa Cruz in 1986 and was a Fulbright Scholar the Weizmann Institute of Science studying biomineralization in 1986 - 1987.EducationDr. Constantz earned a B.A. in aquatic biology and geological sciences from the University of California, Santa Barbara, and an M.S. and Ph. D. in earth sciences from the University of California, Santa Cruz. |
By this ResearcherRelated ContentMagnetic Nanoparticles: From Fabrication to Clinical ApplicationsMagnetic Nanoparticles: From Fabrication to Clinical Applications presents the latest information in magnetic nanoparticle (MNP) research and provides a comprehensive review, from synthesis, characterization, and biofunctionalization to clinical applications of MNPs, including the diagnosis and treatment of cancers. This book features contributions from the most qualified experts in the exciting field and presents
translational research on tailored magnetic nanoparticles for biomedical applications spanning a variety of disciplines.
NanoSensors Monitor Interactions Between Single-Cells in Real-TimeNano researchers at Brigham and Women's Hospital (BWH) have developed a platform technology for cell-signaling sensors that can monitor interactions between single cells – and in real-time. Understanding more about cell signaling events could offer many implications for treatments of disease
FDA Approves Cornell Dots for Human TrialsThe FDA (U.S. Food and Drug Administration) has approved the first clinical trial in humans of Cornell dots, brightly glowing nanoparticles that can light up cancer cells in PET-optical imaging. The technology aims to safely show surgeons extent of tumors in human organs.
|
|||||||||||||||||||||
|
|
||||||||||||||||||||||
Now Online »
CRC Press — 2010 NanoScience and CleanTech catalog
